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Observational epidemiological studies are prone to confounding, measurement error, 
and reverse causation, undermining robust causal inference. Mendelian randomization (MR) 
uses genetic variants to proxy modifiable exposures to generate more reliable estimates of the 
causal effects of these exposures on diseases and their outcomes. MR has seen widespread 
adoption within cardio-metabolic epidemiology, but also holds much promise for identifying 
possible interventions for cancer prevention and treatment. However, some methodological 
challenges in the implementation of MR are particularly pertinent when applying this method 
to cancer aetiology and prognosis, including reverse causation arising from disease latency 
and selection bias in studies of cancer progression. These issues must be carefully considered 
to ensure appropriate design, analysis, and interpretation of such studies.  
In this review, we provide an overview of the key principles and assumptions of MR 
focusing on applications of this method to the study of cancer aetiology and prognosis. We 
summarize recent studies in the cancer literature that have adopted a MR framework to 
highlight strengths of this approach compared to conventional epidemiological studies. 
Lastly, limitations of MR and recent methodological developments to address them are 
discussed, along with the translational opportunities they present to inform public health and 




Obtaining reliable evidence of causal relationships from observational 
epidemiological studies remains a pervasive challenge1-3. While observational studies have 
made fundamental contributions to understanding the primary environmental causes of 
various cancers (e.g., smoking and lung cancer, hepatitis B and liver cancer, asbestos and 
mesothelioma)4-6, recent decades have seen numerous instances of apparently robust 
observational associations being subsequently contradicted by large chemoprevention trials7-
15. Notable translational failures include the ineffectiveness of beta-carotene supplementation 
to prevent lung cancer among smokers in the Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention Study and vitamin E supplementation to prevent prostate cancer in the Selenium 
and Vitamin E Cancer Prevention Trial. Contrary to expectations from observational data, 
findings from both trials suggested that supplementation may increase rather than reduce the 
incidence of cancer8,16.  
Part of the difficulty in translating observational findings into effective cancer 
prevention and treatment strategies lies in the susceptibility of conventional observational 
designs to various biases, such as residual confounding (due to unmeasured or imprecisely 
measured confounders) and reverse causation17,18. These biases frequently persist despite 
energetic statistical and methodological efforts to address them19-21, making it difficult for 
observational studies to reliably conclude that a risk factor is causal, and thus a potentially 
effective intervention target. This issue is likely further compounded by the modern 
epidemiological pursuit of risk factors that confer increasingly modest effects on disease risk, 
which can contribute to a ubiquity of spurious findings in the literature22-24. 
Despite these challenges, observational studies remain crucial for informing cancer 
prevention and treatment policy given issues in translating basic science to human 
populations and because intervention trials are expensive, time-consuming, and often 
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unfeasible in a primary prevention setting. The development of novel analytical tools that can 
help address some of the limitations of conventional observational studies therefore remains 
an important field of research. One such approach known as Mendelian randomization (MR) 
which uses genetic variants to proxy potentially modifiable exposures has seen increased 
adoption within population health research and offers much promise to generate a more 
reliable evidence-base for cancer prevention and treatment. 
 
What is Mendelian randomization? 
MR uses germline genetic variants as instruments (i.e., proxies) for exposures (e.g., 
environmental factors, biological traits, or druggable pathways) to examine the causal effects of 
these exposures on health outcomes (e.g., disease incidence or progression)25-31. The use of 
genetic variants as proxies exploits their random allocation at conception (Mendel’s first law 
of inheritance) and the independent assortment of parental variants at meiosis (Mendel’s 
second law of inheritance). These natural randomization processes mean that, at a population 
level, genetic variants that are associated with levels of a specific modifiable exposure will 
generally be independent of other traits and behavioural or lifestyle factors, although several 
caveats exist (see Table 1). Analyses using genetic variants as instruments to examine 
associations with outcomes have a number of advantages: i) effect estimates should be less 
prone to the confounding that typically distorts conventional observational associations32, ii) 
because germline genetic variants are fixed at conception, they cannot be modified by 
subsequent factors, thus overcoming possible issues of reverse causation, and iii) 
measurement error in genetic studies is often low as modern genotyping technologies provide 
relatively precise measurement of genetic variants, unlike the substantial (and at times 
differential) exposure measurement error which can accompany observational studies (e.g., 




Comparison of Mendelian randomization to Randomized Controlled Trials 
Due to the random allocation of alleles at conception it can be useful to compare the 
structure of a MR analysis to the design of a randomized trial, where individuals are 
randomly allocated at baseline to an intervention or control group (Figure 1). Groups defined 
by genotype should be comparable in all respects (e.g., approximately equal distribution of 
potential confounding factors) except for the exposure of interest. It follows that any 
observed differences in outcomes between these genotypic groups can be attributed to 
differences in long-term exposure to the trait of interest. This latter point is an important 
distinction when interpreting results from a MR analysis as compared to a randomized 
controlled trial: MR will generally estimate the effect of life-long “allocation” to an exposure 
on an outcome, unless an exposure typically occurs only from a certain age - e.g., alcohol 
consumption and smoking - and the genetic proxy affects metabolism of that exposure33. If 
the effect of this exposure on an outcome is cumulative over time, a MR analysis may 
generate a larger effect estimate than that which would be obtained from a randomized trial 
examining an intervention over a limited duration of time. Additionally, if the effect of an 
exposure on an outcome operates primarily or exclusively over a critical or sensitive period 
of the life course (e.g., early childhood), a MR analysis should be able to “capture” a causal 
effect of this exposure but will not be able to distinguish such period effects. In contrast, a 
randomized trial will have the flexibility to test certain interventions over restricted periods of 
follow-up and in individuals who may be within narrow age ranges. These distinctions are 
discussed in more detail in “Cancer Latency and Reverse Causation – benefits of MR”. 
More formally, MR is a form of instrumental variable (IV) analysis that relies on 
three key assumptions: the IV (here, one or more genetic variants) should (i) be reliably 
associated with the exposure of interest; (ii) not be associated with any confounding factor(s) 
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that would otherwise distort the association between the exposure and outcome; and (iii) 
should not be independently associated with the outcome, except through the exposure of 
interest (known as the “exclusion restriction criterion”) (Figure 2a). If all assumptions are 
met, MR can provide an unbiased causal estimate of the effect of an exposure on disease or a 
health-related outcome. Violation of one or more of these assumptions means that 
instruments are invalid and, consequently, that findings from such an analysis may yield a 
biased effect estimate.  
 
Previous success of Mendelian randomization approaches and potential for cancer 
research 
Over the past decade, MR has been increasingly adopted as an analytical approach within 
population health research, particularly the fields of metabolic and cardiovascular disease (CVD), 
where there are several notable examples of important causal inferences. For example, MR has 
suggested a likely causal role of statins on type 2 diabetes (T2D) risk34,35; likely non-causal roles 
of circulating levels of high-density lipoprotein cholesterol (HDL-C) in myocardial infarction36 and 
C-reactive protein (CRP) in T2D37; pointed to the efficacy of proprotein convertase subtilisin/kexin 
type 2 (PCSK9) inhibitors for CHD prevention prior to the publication of confirmatory long-term 
trial results34,38; and prioritized further examination of apolipoprotein B39,40, lipoprotein(a)41 and 
interleukin-642 and de-prioritized fibrinogen43 and secretory phospholipase A(2)-IIA44 as 
intervention targets for CVD. Although this approach has scope to test the effects of an 
increasing number of exposures relevant to cancer through the continued growth in large-scale 
genome-wide association study (GWAS) output, to date there remains a noticeable gap in the 
MR literature with regard to cancer compared to other outcomes (Supplementary Figure 1).  
Here, we provide an overview of some recent studies that have applied MR to cancer 
outcomes, highlighting both the potential strengths compared to conventional 
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epidemiological studies and the unique challenges of performing MR studies in cancer. 
Recent methodological extensions to the original MR paradigm are presented, with emphasis 
on the translational opportunities that they may offer to inform drug target validation and 
public health strategies to reduce the burden of cancer.  
 
Considerations for MR in cancer 
Both the principal strengths of MR and important limitations of this method have 
been discussed in detail previously25-31,45-49. The latter are presented in Table 1 with some 
methodological and statistical approaches that have been developed to address them outlined 
in Box 1a and Box 1b. Some considerations which are specific to investigating causality in 
the setting of cancer are outlined below.  
 
Cancer Latency and Reverse Causation – benefits of MR 
Given long latency periods for many cancers, spurious findings resulting from reverse 
causation are an important concern in cancer epidemiology. Reverse causation has been 
suspected in several instances of ambiguous50-52 or paradoxical findings53 in the cancer 
literature. For example, early studies documenting an association between higher circulating 
cholesterol and lower cancer incidence were variably interpreted as plausible evidence of a 
protective effect of raised cholesterol on cancer risk or as latent cancer leading to a reduction 
in cholesterol levels54-56. With the introduction and widespread usage of low-density 
lipoprotein cholesterol (LDL-C) lowering medications for the prevention and treatment of 
CVD, concern arose that such measures could thus be increasing cancer rates57,58.  
In an early proposal of the use of genetics as a tool to circumvent issues of reverse 
causation in observational data, Katan et al.59 suggested examining the association of genetic 
variants in APOE, determinants of circulating cholesterol levels, with cancer risk. As 
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germline APOE genotype was fixed at conception, it was argued that it would not be 
influenced by subsequent cancer development and could therefore be used to establish 
whether cholesterol had a causal effect on cancer incidence. Subsequent MR analyses testing 
the effect of lifelong elevated cholesterol through genetic variation in APOE, NPC1L1, 
PCSK9, and ABCG8 have reported null associations with overall cancer risk60-62. These 
findings alongside secondary analyses of statin trials showing no effect on cancer rates63 
suggest that – a potential explanatory role of confounding aside - early observational findings 
supporting a protective effect of cholesterol on cancer risk likely reflected undiagnosed 
cancer or early carcinogenic processes causing a reduction in cholesterol levels in pre-
diagnostic samples. 
 
Long-term exposure – benefits of MR 
The advantages of exploiting the fixed nature of germline genotype extends beyond 
addressing reverse causation in observational studies. Large cancer prevention trials are often 
constrained to examining interventions over a limited duration in time and over a particular 
period in the life-course (e.g., middle and/or late adulthood)64. Given the length of time 
required for solid tumor development65, randomized trials will often not allow sufficient 
follow-up for the effect of an intervention to be detected. In turn, long-term chemoprevention 
trials that are conducted may suffer from issues of non-compliance in the intervention arm, 
contamination in the control arm, and attrition during follow-up.  
Further, the optimal timing of an exposure to prevent cancer may be early in the life-
course and therefore may not be adequately addressed in randomized trials66. For example, it 
has been proposed that certain carcinogenic agents or processes may confer an effect, or a 
particularly pronounced effect, only over ‘critical periods’ of early life or adolescence (e.g., 
the influence of inadequate childhood nutrient intake on adult cancer risk or the pubertal 
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period as a window of breast cancer susceptibility)67-71. Interrogating the long-term effect on 
cancer of a given intervention in a prevention trial among children or adolescents would be 
unfeasible.  
Examining the effect of genetic variants allocated at conception can therefore offer an 
important first step in identifying risk factors that may be sensitive to duration or timing of an 
exposure over the life course. Inferences made from promising MR findings to plausible 
intervention effects in a subsequent randomized trial would then need to carefully consider 
the possibility that effect estimates obtained in a MR analysis could be sensitive to critical 
period effects (in which case intervening on an exposure outside of this period may not alter 
disease risk) or represent the cumulative effect of lifelong exposure to a biomarker (in which 
case a relatively short-term trial may generate a smaller effect estimate than that obtained 
from MR). Adopting a “triangulation” framework where evidence from different 
epidemiological approaches with non-overlapping sources of bias are integrated can then be 
used to further examine durations of intervention necessary to confer an effect or ‘pinpoint’ 
possible critical windows of susceptibility to carcinogenic agents72. For example, 
multivariable regression analyses examining the association of an exposure, with some 
evidence of causality from MR studies, over different lengths of follow-up may help to 
identify the duration of exposure required to confer an effect. A negative control study with 
repeat measures of an exposure both within and outside of hypothesized critical periods (e.g., 
dietary fat intake before, during, and after pubertal development), in relation to subsequent 
disease risk (e.g., breast cancer)73 could be used to help refine periods of increased 




Cancer Latency and Reverse Causation – limitations of MR 
Genetic variants known to directly affect an exposure will in some cases be well-
characterized (e.g., variants in APOE), and it will be established whether or not the variant-
exposure associations are influenced by the outcome of interest. The biological understanding 
of other variants associated with risk factors that are identified in GWAS, however, is often 
more limited. In some situations in which genetic variants are associated with both an 
exposure and outcome of interest, the association between a variant and outcome might be 
via the exposure (i.e., a valid IV analysis) but it is also possible that, under certain 
circumstances, there may be a primary effect of the variant on the outcome which in turn 
causes a change in the exposure.  
This situation has been illustrated previously in the context of body mass index (BMI) 
and CRP where an erroneous causal effect can be generated if a genetic variant that primarily 
influences BMI, which in turn influences CRP levels because BMI has a causal effect on 
CRP, is mistaken as being a variant with a primary influence on CRP25. Use of such a variant 
as an instrument for CRP in a MR analysis of the effect of CRP on BMI would then lead to 
biased results.  
This introduction of reverse causation into a MR analysis may be problematic for 
common cancers with long latency periods between tumour initiation and diagnosis (e.g., 
breast and prostate)74. Reverse causation in this context could be mitigated by obtaining gene-
exposure estimates in a healthy population where the prevalence of undiagnosed, latent 
cancer is likely to be low. These estimates could then be used to generate IV estimates in a 
two-sample MR framework. Additionally, steps could be taken to construct an instrument 
solely consisting of genetic variants that plausibly act directly on a trait. For example, in 
constructing an instrument for CRP levels, this could include solely using variants within 
CRP itself as these variants are more likely to be exclusively associated with CRP levels than 
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variants in other genes75. However, it should be noted that a trade-off of using few, 
biologically-informed SNPs as an instrument is that sensitivity analyses examining horizontal 
pleiotropy – when feasible to perform – will have limited statistical power.  
 
Selection bias in cancer progression analyses  
A particular concern in cancer epidemiology is that exposures that influence cancer 
incidence may not influence cancer progression or survival. For example, although smoking 
is a robust risk factor for breast cancer incidence, smoking cessation upon development of 
breast cancer seems to have little effect on subsequent survival76. There has been some 
suggestion that folate may play a dual role in prostate and colorectal carcinogenesis: 
protective against DNA damage prior to the development of neoplasia, but promoting tumour 
progression via enhanced tumour proliferation and tissue invasion once cancer has 
developed77,78.  
Some MR studies have begun to examine the effect of risk factors on both cancer 
incidence and progression79. In a recent analysis examining the effect of alcohol on prostate 
cancer risk in 46,919 men in the PRACTICAL consortium, alcohol consumption was not 
associated with overall prostate cancer risk but increased risk of prostate cancer mortality 
among men with low-grade disease80. Such MR studies exploit the fact that GWAS are being 
increasingly used to identify genetic variants associated with cancer progression or survival 
81,82.  
However, there are important methodological considerations in investigating factors 
causing cancer progression. This is because prognostic studies can suffer from selection bias 
due to the fact that any factors that cause disease incidence (or diagnosis) will tend to be 
correlated with each other in a sample of only cases, even when they are not correlated in the 
source population. Thus if at least one factor causes both incidence and disease survival 
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(hypothetically, insulin resistance in Figure 3), all the other factors which cause disease 
incidence (hypothetically, smoking in Figure 3) will appear to be associated with survival, 
unless the true prognostic factor is conditioned upon. Thus, the estimated effect on 
progression for any factor that is associated with incidence is likely to be biased. However, 
any factor that is not associated with incidence will not suffer from selection bias by studying 
only cases in a MR analysis.  
When conducting prognostic studies, care should be taken to examine and (where 
possible) overcome the selection bias due to studying only cases79. First, the observed data 
could also be used to help identify plausible directed acyclic graphs (DAGs) including both 
disease incidence and progression. For example, if a risk score for a phenotype, and an 
environmental variable, are correlated in cases, but not in the source population this would 
suggest that both factors influence disease incidence, diagnosis, or self-selection into the 
study. However, lack of evidence for such correlations does not imply that there is no 
selection bias, and expert or external knowledge should be used in constructing the DAG, as 
is usual practice. The DAG can then be used to help inform sensitivity analyses. Additional 
data on factors that predict incidence could be combined with observed data in cases, to 
minimise selection bias, either by conditioning or by inverse probability weighting. If more 
than one DAG are considered plausible a priori, then they can be used to conduct sensitivity 
analyses by examining how robust the conclusions are to the causal assumptions made. The 
DAG can also be used to identify which assumptions are being made that are untestable given 
the observed data, and then sensitivity analyses can be conducted by examining plausible 





To illustrate the use of MR in analyses examining cancer outcomes, we have outlined 
three studies that have employed this approach to understand the causal role of various exposures 
on cancer incidence.  
 
Selenium and prostate cancer risk 
Prospective studies reporting inverse associations of dietary, blood, and toenail 
selenium with risk of prostate cancer83-89, along with findings from in vitro studies90,91, led to 
development of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)92. SELECT 
was a 2x2 factorial trial of 35,533 healthy middle-aged men that examined the effect of daily 
supplementation with selenium, vitamin E, or both agents combined, as an intervention for 
prostate cancer prevention. The trial was stopped after 5.5 of a planned 12 years follow-up 
due to a lack of efficacy compounded by possible carcinogenic (increased rates of high-grade 
prostate cancer) and adverse metabolic (some evidence of increased rates of T2D) effects in 
the selenium supplementation group8,9. It is plausible that residual confounding may have 
accounted for conflicting results between prospective studies and SELECT93,94, though others 
have suggested that these differences may have reflected differences in baseline levels of 
selenium of participants in some observational studies as compared to SELECT95.  
To test whether a MR approach could have predicted the results of SELECT, a two-
sample MR analysis (Box 1a) was performed using summary data on 72,729 individuals from 
the PRACTICAL consortium96,97. Eleven single-nucleotide polymorphisms (SNPs) robustly 
associated with blood selenium in previous GWAS98,99 (P<5x10-8) were combined into a 
genetic instrument (Box 1b) to proxy circulating levels of selenium (Figure 1). To allow for 
direct comparison of effect estimates with SELECT, the authors investigated the odds ratio 
(OR) per 114 μg/L increase in circulating selenium, scaled to match the measured differences 
in blood selenium between supplementation and control arms in SELECT.  
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Consistent with results from SELECT, a 114 μg/L life-long increase in blood 
selenium in MR analyses was not associated with overall prostate cancer risk (OR:1.01, 95% 
CI:0.89-1.13; P=0.93; SELECT: Hazard Ratio (HR):1.04, 95% CI:0.91-1.19). MR analysis of 
selenium on advanced prostate cancer (OR:1.21, 95% CI:0.98-1.49; P=0.07) was concordant 
with weak evidence for an increased risk of high-grade prostate cancer in the selenium 
supplementation arm of SELECT (HR:1.21, 95% CI:0.97-1.52; P=0.20). Likewise, the effect 
of selenium on T2D (OR:1.18, 95% CI:0.97-1.43; P=0.11) was consistent with weak 
evidence for an increased risk of T2D in the selenium arm of SELECT (HR:1.07, 95% 
CI:0.97-1.18; P=0.16).  
A limitation of this analysis is that the authors did not test the hypothesis that the 
effect of selenium on prostate cancer risk varied by baseline selenium status. One way to 
investigate this in an MR framework would be to test for interaction in effect estimates by 
study location – whether the study was conducted in selenium replete (e.g. USA) versus 
selenium deficient (e.g. Europe) countries.  If differences in baseline levels of selenium do 
impact on the effect of selenium on prostate cancer, we would expect different effect 
estimates in these different settings.The overall similarities in findings between this MR 
analysis and that of SELECT, as compared to results from conventional observational studies, 
thus provides some support for the utility of an MR approach in approximating experimental 
results using observational data. Further, these results suggest that performing a MR analysis 
may be an important time-efficient and inexpensive step in predicting both efficacy and 
possible adverse effects of an intervention before an RCT is performed.  
 
Alcohol and oesophageal cancer risk 
Regular alcohol consumption is associated with a substantial increased risk of 
oesophageal squamous cell carcinoma in observational studies, with an approximate two-fold 
 16 
 
increased risk for moderate drinkers and five-fold increased risk for heavy drinkers when 
compared to occasional/non-drinkers100. However, alcohol consumption is often associated 
with other lifestyle and behavioural factors (e.g., smoking and dietary intake), which may 
themselves predispose toward oesophageal cancer101,102. Further, most studies that examined 
this hypothesis have used case-control designs, which may introduce reporting bias if cases 
recall alcohol consumption differently from controls100.  
The ability to metabolize acetaldehyde, the principal metabolite of alcohol and a 
carcinogen103, is encoded by ALDH2, which is polymorphic in some East Asian populations. 
Specifically, the ALDH2 *2 allele produces an inactive protein subunit that is unable to 
metabolize acetaldehyde, resulting in markedly higher peak blood alcohol levels in *2*2 
homozygotes compared to *1*1 homozygotes104. Individuals with the *2*2 genotype 
experience a flushing reaction to alcohol, along with dysphoria, nausea, and tachycardia, and 
therefore have very low levels of alcohol consumption105. Consequently, genetic variation in 
ALDH2 is robustly associated with both acetaldehyde levels and alcohol consumption (via 
differences in physiological response to levels of acetaldehyde). This satisfies the 
instrumental variable assumption that an instrument is robustly associated with an exposure 
of interest and ALDH2 can be utilized as an instrument for examining both regular alcohol 
consumption and blood acetaldehyde levels among alcohol consumers106.  
In a meta-analysis of seven studies with a total of 905 oesophageal cancer cases of 
East Asian descent, individuals with the ALDH2 *2*2 genotype were found to have an 
approximately 3-fold reduced risk of oesophageal cancer, as compared to the ALDH2 *1*1 
genotype (OR:0.36, 95% CI:0.16-0.80), suggesting a protective effect of reduced alcohol on 
oesophageal cancer107. However, when comparing individuals with a heterozygous *1*2 
genotype to *1*1 individuals, the former were shown to have a (seemingly paradoxical) 
overall increased oesophageal cancer risk (OR:3.19, 95% CI:1.86-5.47). A naïve 
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interpretation of this finding, without consideration of the effect of the ALDH2 *2 allele on 
blood acetaldehyde, would suggest that individuals with moderate alcohol intake had the 
highest risk of oesophageal cancer. 
When this association was stratified by self-reported alcohol intake, the effect of *1*2 
genotype on oesophageal cancer was shown to differ markedly by alcohol intake. Among 
non-drinkers, there was no strong evidence for an increase in risk among heterozygotes 
(OR:1.31, 95% CI:0.70-2.47) relative to *1*1 individuals. However, among heavy drinkers 
there was a 7-fold increase in risk (OR:7.07, 95% CI:3.67-13.6). Similarly, meta-regression 
analysis showed evidence that level of alcohol intake influenced the effect of the *1*2 
genotype on oesophageal cancer risk (P=0.008) (i.e., the larger the amount of alcohol intake, 
the greater the OR of *1*2 versus *1*1 genotypes). As the possession of an ALDH2 *2 allele 
only appeared to increase risk of oesophageal cancer among heterozygotes who reported 
alcohol intake, this suggested that the substantially elevated acetaldehyde levels in these 
heterozygotes may mediate the effect of alcohol intake on oesophageal cancer.  
More generally, this example illustrates how interpretation of MR findings can be 
challenging when there is limited biological understanding of the genetic variant used as a 
proxy for a given exposure. MR results that appear to be strongly discordant with underlying 
biology should be followed-up alongside available functional understanding of genetic 
variants employed as instruments to help resolve ambiguous or paradoxical results and avoid 
naïve interpretation of findings. 
 
Body mass index and lung cancer risk 
In contrast to the relationship of adiposity with risk of most cancers, BMI has shown 
consistent inverse associations with incidence of lung cancer, particularly among current and 
former smokers108,109. As smoking is a robust risk factor for lung cancer and has an inverse 
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effect on BMI110, some have argued that residual confounding by smoking could account for 
this apparent protective association111. Reverse causation (i.e., undiagnosed lung cancer or 
disease processes leading up to lung cancer prior to study entry influencing subsequent 
weight loss), especially in cohorts with insufficient follow-up time, has also been proposed as 
an explanation for this observational finding112.  
Attempts to address these possible sources of bias have failed to provide clarity. For 
example, studies that reported finely stratifying associations across various dimensions and 
classifications of smoking behaviour (e.g., number of cigarettes smoked per day, “cigarette-
years” smoked, and time since quitting smoking) have found little evidence to support 
residual confounding by smoking influencing this association108,109. Further, studies removing 
individuals with inadequate follow-up have reported little effect on overall 
findings108,109,113,114, interpreted as suggesting that reverse causation is unlikely to be a major 
contributor to this association.  
Given that germline genetic variants associated with BMI cannot be influenced by 
prevalent disease and should not be associated with potential confounding factors, a MR 
approach could be used to assess whether increased BMI is protective against lung 
cancer115,116. For example, Carreras-Torres et al. performed a MR analysis using GWAS 
results on 16,572 lung cancer cases and 21,480 controls of European descent117. 97 SNPs 
previously associated with BMI in a GWAS of 339,224 individuals were compiled into an 
instrument to proxy for anthropometrically measured BMI. This instrument was associated 
with measured BMI but not with available measures of tobacco exposure, including pack-
years, cigarettes smoked per day, or cotinine levels, providing some evidence against 
confounding through measured smoking variables110. In two-sample MR analyses, a 1-SD 
increase in genetically-predicted BMI was weakly associated with an increased risk of lung 




-5). Notably, genetically-predicted BMI was positively associated 
with risk of both squamous cell (OR:1.45, 95% CI:1.16-1.62; P=1.2x10-3) and small cell 
carcinoma (OR:1.81, 95% CI:1.14-2.88;P=0.01) but showed weak evidence for a protective 
effect for adenocarcinoma (OR:0.82, 95% CI:0.66-1.01;P=0.06). These findings thus help to 
clarify a likely positive risk relationship of BMI with two major histosubtypes of lung cancer. 
Alongside some genetic evidence to suggest that elevated BMI may influence subsequent 
smoking uptake118, which itself reduces BMI while increasing lung cancer risk110, these 
findings collectively suggest a possible mechanism that could help to reconcile seemingly 
conflicting MR and observational findings. Further interrogation of a possible mediating role 
of smoking on the causal pathway between BMI and lung cancer risk using “two-step MR” 
(discussed in "MR for mediation") may be able to help shed further light on the possible 
intricate relationship between smoking and BMI in the aetiology of lung cancer. 
 
Recent methodological extensions and future applications  
 
In recent years, the development of various methodological extensions to the original 
MR paradigm have helped to enhance the scope of MR analyses, several of which are 
discussed below with reference to possible applications in cancer epidemiology. 
 
MR for mediation  
Over the past decade, high through-put “omics” technologies have begun to permit 
exhaustive profiling of the epigenome, metabolome, and proteome (as examples), allowing 
the collection of high-dimensional molecular data on increasingly large number of 
individuals119. Such omics measures may serve as important mediators on causal pathways 
linking macro-level risk factors with cancer incidence or progression. While conventional 
mediation analyses exist to examine possible exposure-mediator-outcome relationships, the 
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validity of these approaches relies upon strong assumptions which are unlikely to be met in 
practice, such as no measurement error and no unmeasured confounding120.  
With the performance of GWAS on large collections of metabolites and other omic 
measures121,122, this will create opportunity to develop instruments for these traits. To 
establish whether a particular molecular intermediate is on the causal pathway between an 
exposure and cancer, genetic variants can be used as instruments for both exposures and 
putative mediators that influence a disease outcome in a two-step MR framework (Figure 
4)123.  
For example, a method of testing the mediating role of methylation changes on cancer 
outcomes would be to exploit the fact that genetic variants (e.g., methylation quantitative trait 
loci, mQTLs) are robustly associated with methylation at CpG sites across the epigenome, 
providing possible instruments for MR analyses124. Two-step MR could then used to examine 
the potential mediating role of DNA methylation sites associated with exposures such as 
tobacco smoke125 which have also been found to be strongly associated with lung cancer 
risk126. To test whether methylation is causally mediating (some, or all of) the effect of 
tobacco exposure on lung cancer risk, in the first step, a SNP could be used to proxy smoking 
behaviour in order to investigate its effect on the intermediate phenotype (DNA methylation). 
In the second step, an independent SNP could then be used to proxy the intermediate 
phenotype (DNA methylation) which could then be examined in relation to the disease 
outcome (lung cancer)120. This approach has the potential to be scaled up within the context 
of high dimensional ‘omic datasets to integrate multiple tiers of molecular data in a causal 
framework 127,128. While statistical and computational challenges arise with increasingly 
complex networks of molecular mediators, numerous data reduction and variable selection 
techniques may be used to identify informative causal molecular pathways to disease, 
including pathway analysis, penalised regression, machine learning, and data mining 
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techniques which are increasingly being applied in an automated fashion129,130 (see 
Hypothesis-free MR).       
 
Factorial MR 
Akin to a factorial RCT, factorial MR is a method of testing the independent and 
additive effects of two or more exposures on disease outcomes. This approach was adopted 
by Ference et al. who performed a 2x2 factorial MR analysis to examine the effect of the 
LDL cholesterol-lowering drug ezetimibe on risk of coronary heart disease (CHD), as 
compared to the effect of statins alone or when combined with statins131. Ference et al. 
examined the effect of genetically-lower LDL-C on the risk of CHD through SNPs in 
NPC1L1 (a target of ezetimibe) alone, HMGCR (a target of statins) alone, or variants in both 
gene regions combined. The authors reported that natural randomization to lower LDL-C 
through SNPs in NPC1L1 and HMGCR alone showed similar decreases in LDL-C and CHD 
and that randomization to lower LDL-C in both groups combined had a linearly additive 
effect on LDL-C lowering and a log-linearly additive effect on CHD risk. These results were 
corroborated by the ‘Improved Reduction of Outcomes: Vytorin Efficacy International Trial,’ 
which allocated 18,144 participants to ezetimibe, statins, both, or placebo132.  
An important caveat of this approach is that it relies on access to individual-level data 
and requires very large sample sizes to have adequate statistical power to reliably detect 
differences in effect across groups. 
 
Hypothesis-free MR 
A novel extension to a conventional “hypothesis-driven” MR analysis is a phenome-
wide, “hypothesis-free” MR analysis (termed “MR-PhEWAS”)129. This approach makes use 
of genotyped datasets with high-dimensional phenotypic data or summary GWAS association 
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statistics to perform hundreds or thousands of statistical tests simultaneously in an agnostic 
manner. For example, the approach can be used to examine the effect of a single exposure 
across multiple outcomes or multiple exposures across a single outcome. In contrast to 
hypothesis-driven analyses, hypothesis-free approaches allow for testing hypotheses that may 
not have been considered or tested previously, thus identifying novel risk relationships, and 
can help to address issues of publication bias as all analyses are openly specified and all 
results are presented133.  
For example, using a two-sample MR framework with summary data, Haycock et al. 
performed a MR-PheWAS examining the effect of telomere length on risk of 35 cancers and 
48 non-cancer diseases in 420,081 cases and 1,093,105 controls134. After correction for 
multiple-testing, they found that telomere length increased cancer risk across most sites and 
histological sub-types but reduced CVD risk. An important consideration when performing 
hypothesis-free MR analyses using summary data is the need to follow-up any putative 
findings in subsequent independent datasets. This can be a challenge when using summary 
GWAS data to perform such analyses if a large proportion of the available GWAS literature 
was used to provide causal estimates in the original “discovery phase” of an analysis.  
 
MR for identifying causality of mutational signatures  
Large-scale analysis of the genomes of thousands of cancer patients has helped to 
reveal somatic “mutational signatures” (distinctive somatic mutational patterns left by unique 
carcinogenic agents) involved in the development of their tumours135,136. To date, mutational 
signatures have been identified across more than 30 different cancer types, with anywhere 
from two to six distinction mutational processes for each cancer type. Knowledge of the 
causes of somatic mutations within tumour tissue can improve understanding of the 
mechanisms by which endogenous and exogenous exposures promote the development of a 
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cancer. Of the mutational signatures identified across cancer types, a putative cause has been 
proposed for approximately half135; MR may offer particular promise in helping to identify 
the aetiology of other mutational signatures identified137.  
Robles-Espinoza et al. examined the effect of germline MC1R status, associated with 
red hair, freckling, and sun sensitivity, on somatic mutation burden in melanoma. Such an 
analysis can be viewed as a MR appraisal of the effect of this sensitivity phenotype on 
somatic mutation burden in melanoma138. For all six mutational types assessed, there was 
evidence of an increased burden of somatic single nucleotide variants in individuals carrying 
one or two MC1R R alleles (disruptive variants). For one of the six mutational signatures 
characterized by an abundance of somatic C>T single nucleotide variants, each additional R 
allele at MC1R was associated with a 42% (95% CI:15-76%) increase in the C>T single 
nucleotide variant count. This approach therefore highlights the possibility of testing the 
causal effect of suspected carcinogenic agents on mutational burden for various mutational 
signatures across cancer tissues and sub-types.  
 
Drug repurposing and adverse drug effects 
Drug repurposing, applying known drugs to novel indications, can provide a rapid, 
cost-effective mechanism for drug discovery and may hold promise for the development of 
pharmacological interventions for cancer prevention139,140. In turn, for well-tolerated drugs 
that are considered candidates for repurposing, MR may offer an attractive approach for 
testing their potential chemopreventive efficacy. For example, it is currently possible to 
reliably instrument drugs for which there is a broad understanding of the biological 
mechanism of action (e.g., HMG Co-A reductase inhibitors, PCSK9 inhibitors, CETP 
inhibitors, and sPLA2 inhibitors in cardiovascular disease141). For the primary or tertiary 
prevention of certain cancers, aspirin, metformin, and bisphosphonates have all been 
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proposed as possible candidate pharmaceutical agents for repurposing142-144. Using MR as a 
first step to test drug efficacy for novel cancer indications could help to prioritize or 
deprioritize which drugs should be taken forward to testing in RCTs for re-purposing.  
MR may also provide a useful approach for predicting adverse effects of 
pharmaceuticals145. Pre-approval trials are often not able to adequately capture development 
of adverse effects due to the comparatively small number of individuals typically exposed to 
a drug in such trials (unless drug effects are very common or very large), the limited duration 
of most trials, and unknown generalizability of trial participants to the broader population. 
While many of these issues can be addressed post-approval of a drug through spontaneous 
reporting systems, these introduce their own limitations including confounding, for example 
by indication, environmental factors, or lifestyle traits. MR studies should be able to 
overcome these limitations and have been employed in some instances to test or anticipate 
adverse effects of interventions in ongoing trials (e.g., adverse effects of statins on T2D as 
proxied by variants in HMGCR)34,35,146-148.  
While knowledge of biological pathways can help to anticipate some adverse drug 
effects pre-approval of a drug, it may not be possible to correctly predict all such effects149. 
One possible approach to resolve this would be to use MR-PhEWAS to perform a phenotypic 
scan of a genetically-instrumented drug exposure across hundreds or thousands of potential 
outcomes, as outlined previously. The identification of possible adverse effects of a drug 
through this approach could then be used to pre-specify and adequately power secondary 





Observational epidemiological studies are prone to various intractable biases which 
can undermine robust causal inference. Mendelian randomization offers a promising 
approach to generate a more reliable evidence-base for cancer prevention and treatment. The 
advent of MR methods using summarized data means that such analyses can now be 
performed more efficiently, rapidly, and with greater statistical power than previously 
possible. Further, the range of methodological extensions to the original MR paradigm now 
available have greatly expanded the scope of this approach, enabling increasingly 
sophisticated causal questions to be interrogated150. Despite this, there are inherent 
constraints on the types of epidemiological questions that can be answered with this approach 
as compared to conventional observational analyses. For example, MR is restricted to 
examining exposures that have a heritable component and suitable genetic proxies for these 
exposures; MR cannot isolate critical period effects for exposures; and MR will usually only 
represent the effect of lifelong exposure to a biomarker. These limitations mean that 
inferences made from MR will be most informative when integrated alongside insights 
gained from other epidemiological approaches and study designs. Given optimism 
surrounding use of the method in helping to strengthen evidence for public health and 
pharmacological interventions151, it is likely that there will be a continued proliferation of 
MR analyses in the literature in the near future. Careful design, analysis, and interpretation of 
such studies with consideration of the limitations of the method will provide the greatest 








Mendelian randomization (MR), instrumental variable (IV), cardiovascular disease (CVD), 
type 2 diabetes (T2D), high-density lipoprotein cholesterol (HDL-C), C-reactive protein 
(CRP), proprotein convertase subtilisin/kexin type 2 (PCSK9), genome-wide association 
study (GWAS), low-density lipoprotein cholesterol (LDL-C), body mass index (BMI), 
directed acyclic graphs (DAGs), Selenium and Vitamin E Cancer Prevention Trial 
(SELECT), genome-wide association study (GWAS), single-nucleotide polymorphisms 
(SNPs), methylation quantitative trait loci (mQTLs), coronary heart disease (CHD), 
Mendelian randomization phenome-wide association study (MR-PheWAS), linkage 
disequilibrium (LD), Genetic Associations and Mechanisms in Oncology (GAME-ON), 
waist-hip ratio (WHR), genetic risk score (GRS), inverse-variance weighted (IVW), weighted 
median estimator (WME), mode-based estimate (MBE), instrument strength independent of 
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Table 1. Limitations of Mendelian randomization and techniques available to address them  
Limitation Description Techniques to Address Limitation 
Limitations to robust causal inference 
Horizontal 
pleiotropy 
A genetic variant affecting an outcome via a 
biological pathway independent of the exposure 
under investigation, violating the “exclusion 
restriction criterion” 
Assessment of heterogeneity across 
individual SNP estimates  
MR-Egger regression and intercept test 
Median-based approaches 
Mode-based approaches 
Sensitivity analysis removing potentially 
pleiotropic SNPs 
Restrict risk score to SNPs in well-
characterized genes 
Stratification by exposure status (e.g., 




Linkage disequilibrium (LD) is the non-random 
association of alleles at different loci that are close 
in proximity on a chromosome. If a certain SNP is 
being used as an instrument for an exposure in a 
MR analysis, and this SNP is in LD with another 
SNP that affects the outcome via an independent 
pathway, then the assumptions for MR will be 
violated 
LD pruning of SNPs prior to MR 
analysis 
Weighted generalized linear regression 
Perform studies in populations with 




Allele frequencies vary among populations of 
different genetic ancestry, and similarly, disease 
risk often varies among populations of different 
genetic ancestry, which could introduce genetic 
confounding into a MR analysis, potentially 
resulting in spurious causal estimates 
Restricting analyses to individuals of a 
homogenous genetic ancestry 
Genomic inflation factor calculation 
Adjusting MR analysis by genetic 
ancestry or ancestry-informative 
principal components  
Trait 
heterogeneity 
For a given trait (e.g., adiposity), SNPs may 
influence various dimensions of this trait (e.g., both 
overall and visceral adiposity) but GWAS have 
only examined associations with a subset of these 
dimensions (e.g., solely BMI). This may produce 
misleading inferences if the aim of an analysis is to 
ascertain the causal effect of a particular dimension 
of a trait.  
Better understanding of complex 
phenotypes  
Multivariable MR  
 
Limitations that complicate interpretation 
Canalization Developmental compensation against the effect of 
a genetic variant being used as an instrument that 
could attenuate the magnitude of an observed MR 
association towards the null 
Knowledge of the period of life when the 
influence of a genetic variant(s) on an 
exposure may emerge can help guide 
whether developmental compensatory 
processes are plausible. For example, 
behavioural exposures that typically 
occur after fetal development (e.g., 
alcohol, smoking) will be unlikely to be 
influenced by canalization whereas in 
utero exposure may. There are currently 
no approaches for evaluating suspected 
canalization in MR analyses. 
Complexity of 
association  
Misinterpretation of MR results can arise from 
limited biological understanding of genetic variants 
utilised as IVs. Examples include interpretation of 
the effect of the heterozygous ALDH2 genotype on 
oesophageal cancer risk (discussed in “Illustrative 
examples”) and previous MR analyses that have 
examined the effects of interleukin-6 42  and  
extracellular superoxide dismutase 152 on CHD risk 
(discussed in more detail elsewhere 49).  
Improved biological understanding of 
genetic variants with functional 




Dynastic effects In certain circumstances, it is possible that parental 
genotype can confound an association of offspring 
genotype with offspring disease risk. For example, 
genetic variants influencing parental height will not 
only influence offspring height genotype but could 
also influence offspring disease risk via an 
independent effect of maternal height-raising 
alleles on the in utero environment of the offspring 
153,154.  
Between-sibling MR design 
Within-family MR design 
Critical period 
effects 
If a biomarker primarily influences disease risk 
over a critical or sensitive period of the life course, 
a MR estimate should capture the causal effect of 
this biomarker but may not be able to distinguish 
period effects  
Negative exposure control design 
Weak 
instrument bias 
If IV is not robustly associated with the exposure, 
estimates will be biased towards the observational 
estimate in a one-sample setting and towards the 
null in a two-sample setting 
Increase sample size  
Genetic risk scores or combining 
summarized data from multiple genetic 
variants 




Chance correlation between genetic variants and 
confounders can introduces an overestimation of 
the effect of a “lead” genetic variant on an 
exposure of interest in the discovery stage of a 
GWAS. The effect of this phenomenon will depend 
on the degree of overlap of participants in the 
GWAS discovery dataset and subsequent MR 
analyses. In a one-sample MR setting with a binary 
outcome, winner’s curse should not lead to bias if 
control participants were used in the discovery 
GWAS. If both cases and controls were used in the 
discovery dataset, this will lead to weak instrument 
bias. If the instrument is identified in a sample 
independent to the one in which MR analysis is 
performed, this will lead to an underestimate of the 
causal effect.  
Two-sample MR analysis 




Genetic variants typically explain a small amount 
of variance for a given exposure, thus MR requires 
large sample sizes to test hypotheses with adequate 
power. Furthermore, in finite samples, confounders 
may not be perfectly balanced between genotypic 
groups 
Large GWAS and GWAS consortia 
Genetic risk scores or combining 
summarized data from multiple genetic 
variants 








Historically, both gene-exposure and gene-outcome estimates in MR analyses had to be obtained from a 
single sample which relied upon the availability of information on genotype, exposure, and outcome among all 
participants in that dataset. In practice, this not only posed a challenge in that large-scale measurement of a given 
exposure of interest (e.g., many molecular traits) may not only be prohibitively expensive but also that 
measurement of certain exposures may not be possible (e.g., if adequate blood sample collection or preservation 
has not taken place)155. An extension to the original MR paradigm that has allowed MR analyses to overcome 
some of these challenges is the integration of gene-exposure and gene-outcome estimates from two independent 
(non-overlapping) datasets into a single analysis, an approach called “two-sample MR” analysis155,156.  
 
Two-sample MR with summarized genetic association data 
 
It is possible and increasingly common practice to perform MR analyses exclusively using summarized 
data on gene-exposure and gene-outcome estimates156,157. A strength of two-sample MR with summary data is that 
the scope of possible MR analysis can be expanded significantly by exploiting the growing  amount of publicly-
available summary data from large genome-wide association study (GWAS) consortia158  and is aided by the 
development of a harmonised MR platform that has collated these datasets (MR-Base)159. Utilizing data from 
separate exposure and outcome samples can help to bolster statistical power in MR analyses by increasing the 
overall sample size of an analysis, particularly when testing effects on binary disease outcomes like cancer, and 
also reduces the likelihood of “winner’s curse” bias (see Table 1)156. This increased power also means that 
sensitivity analyses to test pleiotropy assumptions (see Box 2) which are often statistically inefficient are better-
powered to detect violations of these assumptions. Furthermore, whereas in a one-sample MR setting weak 
instruments can bias effect estimates towards the observational effect, resulting in potential false positive 
associations, in a two-sample setting weak instrument bias distorts findings towards the null. Thus, conducting 
both analyses is a form of sensitivity analysis that provides bounds to a possible causal effect. 
To test whether height has a causal effect on risk of colorectal, lung, and prostate cancer, Khankari et al. 
used a two-sample MR approach. This employed: i) summarized gene-exposure estimates from a panel of 423 
single-nucleotide polymorphisms (SNPs) previously found to be associated with height in a large GWAS meta-
analysis (GIANT consortium; N=253,288) and collectively explaining approximately 16% of variance in height; 
and ii) summarized gene-outcome estimates from a total of 47,800 cancer cases (across the three outcomes 
ascertained) and 81,533 controls from the Genetic Associations and Mechanisms in Oncology (GAME-ON) 
consortium160. This approach allowed robust causal inference with adequate statistical power. While Khankari et 
al. did not examine the effects of height across stage/grade or histological sub-type of the three cancers examined, 
two-sample approaches enable statistically efficient examination of risk factors across such stratified groups which 
may have limited sample sizes. 
 
Limitations of two-sample MR 
 
While two-sample MR offers some clear advantages over a conventional one-sample approach, it also 
introduces additional assumptions. One important assumption is that the separate datasets from which gene-
exposure and gene-outcome associations are obtained are representative of the same underlying population, for 
example with regard to sex, age, ethnicity, or genetic profile. While most GWAS that have examined sex-specific 
associations of traits have often reported at most modest evidence of sexual dimorphism161,162, given the sex-
specific nature of certain cancers, care should be taken to ensure that instruments are obtained from sex-stratified 
GWAS for analyses of these cancers when available. For example, in examining the effect of waist-hip-ratio 
(WHR) on endometrial or ovarian cancer this could involve using the 34 SNPs associated with WHR in women 
exclusively as a primary instrument, then comparing results with those obtained using the 47 SNPs associated with 
WHR across both sexes as a sensitivity analysis163,164. Concordance of findings between both approaches may 
suggest that directionally-consistent SNPs associated with WHR at genome-significance in women, but not men, 
simply reflected reduced statistical power in sex-stratified GWAS analyses and not genuine heterogeneity in SNP-
effects between sexes. A second challenge when performing two-sample MR using summary data is the difficulty 
in examining the IV assumption that an instrument used is independent of exposure-outcome confounders. While 
restriction of analyses to ethnically homogenous gene-exposure and gene-outcome datasets will reduce the 
possibility of confounding through population stratification, in lieu of data on measured potential confounders, 
this assumption cannot be directly tested. While one way of approximately testing this assumption is performing 
look-up of associations of SNPs with suspected potential confounders in curated GWAS databases, this would not 
preclude chance confounding relationships arising in the dataset(s) from which summary data were obtained. 
Third, with the use of summary data from large GWAS consortia, it is possible that there may be some participant 
overlap in the datasets from which gene-exposure and gene-outcome associations are obtained. If overlap is small, 
this should not substantially bias effect estimates, however substantial overlap will bias MR toward the 
observational effect165.  
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Box 1b: Genetic risk scores and pleiotropy 
 
Using multiple genetic variants as an instrument 
 
While GWAS over the past decade have been successful at identifying robust associations between 
common genetic variants (usually SNPs) and thousands of phenotypes, the effects of individual variants on traits 
are often modest166. Consequently, statistical power for MR analyses using single variants as instruments can be 
limited. A common approach of overcoming limited statistical power is to combine multiple variants into a 
genetic risk score (GRS) or combine summary data across multiple SNPs, which increases the variance 
explained for a trait of interest, improving instrument strength167,168. A GRS or instrument with summarized data 
from multiple SNPs can consist of an unweighted summation of risk-factor increasing alleles across variants but, 
more commonly, a weighted approach is used (e.g., weighted by the estimated SNP-exposure effect size or, in 
settings with summary data, by the inverse of the standard error of the gene-outcome association – called the 
“inverse-variance weighted (IVW) method”). In a two-sample setting (see Box 1), an instrument consisting of 
summarized data from multiple variants will typically be constructed by combining SNPs that are independent 
(i.e., not in LD with each other). However, it is also possible to combine correlated SNPs in low to moderate LD 
into an instrument, using weighted generalized linear regression for example167. This requires the creation of a 
weighting matrix which takes into account correlations between SNPs, often with use of a reference panel like 
the Hapmap or the 1,000 Genomes Project169,170, which is then used to correctly inflate standard error estimates. 
The latter method may be preferable to overcome weak instrument issues when few independent SNPs are 
available.  
 
Vertical vs horizontal pleiotropy 
 
While construction of a GRS can help to enhance statistical power in MR analyses, increasing the 
number of variants included in a score is accompanied by an increased probability that any of these variants 
could be pleiotropic (i.e., one variant having effects on two or more traits). In a genetic epidemiological context, 
an important distinction is made between vertical and horizontal pleiotropy, each having different effects on the 
interpretation of MR findings. Vertical pleiotropy occurs when one variant has an effect on two or more traits 
that both influence an outcome through the same biological pathway. For example, variants in FTO that not only 
associate with BMI, but also with fasting insulin and glucose concentrations would be consistent with a causal 
effect of BMI on these downstream traits171. In this case, a MR analysis examining the effect of BMI on T2D 
risk using these FTO variants would be consistent with an instrument (genetic variants associated with BMI) 
influencing an outcome (T2D) exclusively through the exposure of interest (BMI). This form of pleiotropy 
would be expected in complex biological systems and does not pose a threat to the validity of a MR analysis172. 
In contrast, horizontal pleiotropy occurs when one variant has an effect on two or more traits that influence an 
outcome through independent biological pathways. For example, genetic variants associated with triglyceride 
levels also show substantial overlap with variants associated with LDL-C and HDL-C173. As a putative effect of 
triglyceride-increasing variants on CHD risk may not only operate through elevation of triglycerides but through 
alternate cholesterol pathways, a naïve MR analysis using all triglyceride-increasing variants without addressing 
pleiotropy in this instance could invalidate the “exclusion restriction criterion” IV assumption. The presence of 
horizontal pleiotropy thus poses a direct threat to the validity of MR findings.  
 
Assessment of horizontal pleiotropy 
 
When using either a single or a small number of genetic variants as IVs, the presence of horizontal 
pleiotropy for any individual variant can be assessed through SNP look-ups in curated GWAS databases with 
complete summary data (e.g., MR-Base159, PhenoScanner174, dbGap175) to examine whether associations for a 
given SNP have been reported for traits other than the exposure of interest. Sensitivity analyses can then be 
performed by dropping variants that are suspected to be horizontally pleiotropic and then carefully interpreting 
pooled causal estimates with and without suspected horizontally pleiotropic SNPs. When an instrument consists 
of multiple genetic variants, an important first step in examining the presence of horizontal pleiotropy in 
analyses is to assess heterogeneity in causal estimates across individual IVs (including visually examining 
heterogeneity using a funnel plot). While substantial heterogeneity in causal estimates may be indicative of the 
presence of horizontal pleiotropy, if there is overall symmetry in the funnel plot, pleiotropic effects will be 
balanced (termed “balanced pleiotropy”) and the overall causal estimate generate will be unbiased. In contrast, if 
there is considerable asymmetry in a funnel plot, this will suggest that horizontal pleiotropic effects of individual 
IVs are not balanced and that overall causal estimates will be biased (termed “directional pleiotropy”). MR-
Egger regression and the weighted median estimator (WME) are two widely implemented approaches for 
detecting and accounting for directional pleiotropy, and are applicable to analyses utilizing individual-level and 
summary-level data176,177. An additional approach called the mode-based estimate (MBE) has also recently been 
proposed as a method to examine horizontal pleiotropy in MR analyses178. All of these methods can help to 
detect IV violations while making different assumptions about the nature of horizontal pleiotropy and thus, when 
feasible, using all approaches as sensitivity analyses in a given MR analysis can serve as an important 
















Sensitivity analyses to examine horizontal pleiotropy when using multiple genetic variants 
 
MR-Egger regression provides a consistent causal effect estimate even when all genetic variants are 
invalid IVs because they violate the exclusion restriction criterion. This approach performs a weighted linear 
regression of the gene-outcome coefficients on the gene-exposure coefficients with an unconstrained intercept 
term. If the IV assumption that the association of each variant with the outcome is mediated exclusively 
through the exposure of interest is met, this intercept term should be zero. An intercept term that differs from 
zero would suggest the presence of unbalanced pleiotropy, thus providing a test for directional pleiotropy. In 
turn, the slope coefficient in MR-Egger regression will provide an estimate of a causal effect adjusted for 
directional pleiotropy. An important consideration when using MR-Egger is that it works under the InSIDE 
(instrument strength independent of direct effect) assumption. In essence, InSIDE assumes that no association 
exists between the strength of gene-exposure associations and the strength of bias due to horizontal pleiotropy. 
Intuitively, if multiple genetic variants in an MR analysis have horizontally pleiotropic effects through 
unrelated intermediate variables, it would be expected that this assumption should hold. However, this 
assumption is unlikely to be satisfied in situations where all pleiotropic effects are due to the presence of a 
single confounder. As such, in lieu of an established method of formally testing the InSIDE assumption, 
interpretation of intercept terms and slope coefficients generated through MR-Egger should be made with this 
assumption in mind. A complementary sensitivity analysis to MR-Egger is the weighted median estimator. 
This approach provides an estimate of the weighted median of a distribution in which individual IV causal 
estimates in a risk score are ordered and weighted by the inverse of their variance. Unlike MR-Egger which can 
provide an unbiased causal effect even when all IVs are invalid, WME requires that at least 50% of the 
information in a risk score is coming from IVs that are valid in order to provide a consistent estimate of a 
causal effect in a MR analysis. However, an advantage of WME is that it provides improved precision as 
compared to MR-Egger and does not rely on the InSIDE assumption. The mode based estimator generates a 
causal effect using the mode of a smoothed empirical density function of individual IV causal estimates in a 
risk score. This approach operates under the assumption that the most common effect estimate of individual 
IVs in a risk score arises from valid instruments (called the Zero Modal Pleiotropy Assumption, or ZEMPA). If 
this assumption holds, the mode can provide a consistent causal estimate even if most of the (non-modal) IVs 
are invalid. Both simple and weighted mode approaches (weighted by the inverse variance of the SNP-outcome 
association) can be utilized. Mode-based approaches have less power to detect a causal effect than the weighted 
median estimator but greater power than MR-Egger regression under the condition of no invalid instruments. 
Similar to the weighted median estimator, mode-based approaches are also (by default) less susceptible to bias 




Figure 1. Schematic comparison of the structure of a randomized controlled trial (SELECT) 
and a Mendelian randomization analysis (PRACTICAL)  
 
In SELECT (left), individuals were randomly allocated to the intervention (200 μg daily 
selenium supplementation, which lead to a 114μg/L increase in blood selenium) or control 
group (placebo). In PRACTICAL (right), the additive effects of selenium-raising alleles at 
eleven SNPs, randomly allocated at conception, were scaled to mirror a 114μg/L increase in 
blood selenium. If an RCT trial is adequately sized, randomization should ensure that 
intervention and control groups are comparable in all respects (e.g., distribution of potential 
confounding factors) except for the intervention being tested. In an intention-to-treat analysis, 
any observed differences in outcomes between intervention and control groups can then be 
attributed to the trial arm to which they were allocated. Likewise, in a MR analysis, groups 
defined by genotype should be comparable in all respects (e.g., distribution of both genetic 
and environmental confounding factors) except for their exposure to a trait of interest. Any 
observed differences in outcomes between groups defined by genotype can then be attributed 












Figure 2. Illustration of MR methodology  
 
(A) A genetic variant (G) is used as a proxy for a modifiable exposure (E) to assess the 
association between E and an outcome of interest (O) without the issues of reverse causation, 
and confounding (U). MR methodology relies on three main assumptions, in that G must (i) 
be reliably associated with E; (ii) not be associated with U; and (iii) not be independently 
associated with O, except through E. This method is exemplified in the context of assessing 
the association of smoking and lung cancer (B), using the CHRNA5-A3-B4 SNP as a genetic 
instrument for heaviness of smoking.  
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Figure 3. Directed acyclic graph for selection bias in prognostic studies  
 
In this example, the square bracket indicates that we are conditioning on pancreatic cancer 
incidence in a survival study by only studying pancreatic cancer cases, thus inducing an 
association between smoking (a factor that is otherwise independent of pancreatic cancer 
survival) and pancreatic cancer survival. This link is broken when conditioning on the factor 
that influences both cancer incidence and survival (e.g., insulin resistance), which can 
otherwise be seen as a confounder of the association between smoking and cancer survival. If 
a factor appears to influence pancreatic cancer survival that is not associated with pancreatic 
cancer incidence (e.g., treatment for pancreatic cancer), selection bias in such an MR analysis 
















Figure 4. Two-step Mendelian randomization analysis examining the mediating effect of 
methylation on the association between smoke exposure and lung cancer 
 
In the first step, a SNP within CHRNA5-A3-B4 is used as an instrument for smoke exposure 
to assess the causal association between smoking and DNA methylation. In the second step, 
an independent cis-SNP is used as an instrument for DNA methylation to assess the causal 
association of DNA methylation with lung cancer risk. The two-step method allows 
interrogation of the mediation effect of DNA methylation in the association between smoking 
and lung cancer risk. 
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